Articles by Tyler Menichiello

  1. Political Influences And Regulatory Implications For Biotech In 2025 12/27/2024

    In this segment of the executive roundtable discussion, our panelists discuss the changing political landscape and its potential effects from a regulatory and economic point of view.

  2. 2025 Predictions For AI Use In Biotech 12/26/2024

    In this segment of the executive roundtable discussion, our panelists discuss the growing prevalence of AI and its implications, both good and bad. They share their thoughts on smart adoption and the need for regulatory guidance moving forward.

  3. Cell Therapy Manufacturing Trends And Advancements Continuing In 2025 12/26/2024

    In this segment of the executive roundtable discussion, our panelists reflect on recent advances in cell therapy manufacturing and discuss active areas of innovation.

  4. Exciting Areas Of Innovation For Cell Therapies 12/23/2024

    In this segment of the executive roundtable discussion, our panelists express optimism about the promising future of allogeneic cell therapies and discuss other innovations in the field.

  5. Leveraging Directed Evolution To Optimize AAV Vector Design 12/18/2024

    4D Molecular Therapeutics (4DMT) CEO and co-founder, David Kirn, MD, talks about the company’s approach to vector optimization, its product development, and its stage-appropriate buildup of internal GMP manufacturing.

  6. Developing Bespoke Antisense Oligonucleotides To Treat Rare Diseases 11/26/2024

    EveryONE Medicines CEO, Kent Rogers, explains the company’s mission to address a major unmet need in children with rare neurodegenerative diseases, one patient at a time.

  7. Allogene's Mission To Democratize CAR-T 11/22/2024

    Allogene Therapeutics CEO and co-founder, David Chang, MD, Ph.D., talks about the exciting future of allogeneic CAR-T and shares the company's mission to bring these therapies to patients.

  8. Regeneron's Strategy To Address Congenital Deafness 10/30/2024

    Regeneron's Jonathon Whitton, Au.D., Ph.D., and Christos Kyratsous, Ph.D., discuss the company's clinical and developmental strategy for DB-OTO, a gene therapy to treat congenital deafness.

  9. Tune Therapeutics On Clinical Readiness, Technology Adoption 10/16/2024

    Heidi Zhang, Ph.D., explains Tune Therapeutics' epigenetic approach to gene therapy and how the company is preparing its lead candidate for the clinic, as well as it's modular approach to automation.

  10. How Platform Technologies Are Shaping The Gene Therapy Landscape 9/30/2024

    Leading experts in gene therapy discuss CMC strategy for platform technologies, product lifecycle management, and the role CDMOs play in moving the space forward.